Who is sponsoring NCT04339829?

NCT04339829 is sponsored by Guangdong Association of Clinical Trials.

What drugs are being tested in NCT04339829?

Interventions in NCT04339829: Dacomitinib.

Is NCT04339829 still recruiting?

NCT04339829 is currently status unknown. Last updated 9 April 2020.

Last reviewed 2020-04-09 · How we verify

NCT04339829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Status unknown Phase 2 Last updated 9 April 2020

What this trial tests

Phase 2 trial testing Dacomitinib in Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases in 50 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 July 2022

30 August 2023

Quick facts

Lead sponsor	Guangdong Association of Clinical Trials
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 August 2020
Primary completion	1 July 2022
Estimated completion	30 August 2023

Drugs / interventions tested

Dacomitinib (Dacomitinib) — full drug profile →

Conditions studied

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases — all drugs for Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases →

Sponsor

Guangdong Association of Clinical Trials

Who can join

Adults 18 to 80, any sex, with Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
Zhang J, Wang Y, Liu Z, Wang L, et al · · 2021 · cited 26× · PMID 34751504 · DOI 10.1111/1759-7714.14222
Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer.
Wen J, Yu JZ, Liu C, Ould Ismail AAO, et al · · 2024 · cited 13× · PMID 38396722 · DOI 10.3390/ijms25042044
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
Jung HA, Park S, Lee SH, Ahn JS, et al · · 2023 · cited 10× · PMID 38016250 · DOI 10.1016/j.esmoop.2023.102068
Metastatic brain tumors: from development to cutting-edge treatment.
Tanzhu G, Chen L, Ning J, Xue W, et al · · 2025 · cited 8× · PMID 39712454 · DOI 10.1002/mco2.70020
Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).
Kariri YA. · · 2025 · PMID 41096039 · DOI 10.3390/jcm14196960
Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study.
Yu Y, Pan Y, Zhou J, Mu S, et al · · 2025 · PMID 40811939 · DOI 10.1016/j.lungcan.2025.108710
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study.
Xing P, Pu X, Zhou Y, Liu Z, et al · · 2025 · PMID 40349136 · DOI 10.1093/oncolo/oyaf079

Verify or expand the search:

Other trials of Dacomitinib

Trials testing the same drug.

NCT05271916 — First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations · Phase 1, PHASE2 · recruiting
NCT04609319 — Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small · completed
NCT04504071 — Dacomitinib in Lung Cancer With Uncommon EGFR Mutations · Phase 2 · active not recruiting
NCT04675008 — Central Nervous System(CNS) Efficacy of Dacomitinib · Phase 2 · unknown
NCT04768491 — Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC · unknown

Other Guangdong Association of Clinical Trials trials

Trials by the same sponsor.

NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04339829 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
Last refreshed: 9 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04339829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing